AOD-9604: A Research Overview of the hGH Fragment
AOD-9604 is a synthetic 16-residue peptide derived from the C-terminal region of human growth hormone (hGH). It was designed to isolate a fragment associated with fat-metabolism activity from the rest of the hormone, and it has since become one of the more frequently discussed small peptides in metabolic research. This overview covers the structure of AOD-9604, the origin of the fragment, what the animal literature has measured, how its clinical development ended, and the handling and verification considerations relevant to laboratory work.
Origin and Chemical Structure
Human growth hormone is a 191-residue protein secreted by pituitary somatotrophs. Its biological activity is broad, spanning growth-promoting, anabolic and metabolic effects, and these are mediated through the growth hormone receptor and downstream signalling, including insulin-like growth factor 1 (IGF-1). Early structure-function work suggested that different regions of the molecule contribute to different activities, and that a short stretch near the C-terminus, residues 176–191, was associated with effects on lipid metabolism rather than with growth. This observation motivated the synthesis of fragments that might reproduce the metabolic activity without engaging the full receptor-mediated pathway.
AOD-9604 corresponds to hGH(176–191) with one deliberate change: a tyrosine residue is added at the N-terminus. The one-letter sequence is YLRIVQCRSVEGSCGF, and the two cysteine residues form an intramolecular disulfide bond, giving a small cyclic loop within an otherwise linear chain. The molecular formula is C78H123N23O23S2, the molar mass is approximately 1,815 g/mol, and the CAS registry number is 221231-10-3. The added tyrosine is generally described as providing a convenient site for labelling and analytical detection, and it does not alter the cysteine bridge that defines the fragment’s conformation.
Because it is a short peptide of well under 2,000 Da, AOD-9604 is chemically accessible by solid-phase synthesis and is relatively simple to characterise compared with larger hormone analogues. That same simplicity makes identity confirmation by mass spectrometry straightforward, a point returned to below.
Preclinical Findings in Animal Models
The foundational animal work was reported in the early 2000s by a group working with Frank Ng and colleagues. Ng and colleagues (Hormone Research, 2000) published metabolic studies of the synthetic lipolytic domain, describing AOD-9604 as a fragment that retained fat-metabolism activity in rodent models. The most frequently cited mechanistic paper is Heffernan and colleagues (Endocrinology, 2001), which examined chronic treatment with hGH and AOD-9604 in obese mice and in mice lacking the β3-adrenergic receptor.
In that study, 14 days of intraperitoneal treatment with either hGH or AOD-9604 reduced body weight and body fat in obese mice. These changes coincided with increased expression of β3-adrenergic receptor RNA, the principal lipolytic receptor in adipocytes, which was suppressed in the obese animals and was raised towards the level seen in lean mice. In β3-receptor knockout mice, chronic treatment did not reproduce the weight loss or increased lipolysis observed in wild-type animals, indicating that the receptor contributed to the chronic response.
The authors also reported a nuance that is often lost in secondary summaries. In an acute experiment, AOD-9604 still increased energy expenditure and fat oxidation in the knockout animals. From this, Heffernan and colleagues concluded that the lipolytic actions of hGH and AOD-9604 are not mediated directly through the β3 receptor, even though both agents raise its expression, an effect that may increase the sensitivity of adipose tissue to lipolytic signals. The precise receptor interaction of the fragment therefore remains less clearly defined than the pathway for full-length hGH.
Distinction From Growth Hormone Activity
A central feature of the fragment’s research profile is that it was characterised as lacking the growth-promoting and insulin-antagonising properties of the parent hormone. Native hGH can reduce insulin sensitivity and raise IGF-1, whereas the reports on AOD-9604 describe a molecule that did not stimulate IGF-1 production in the models examined. This is why the peptide is discussed as a tool for separating the lipid-metabolism component of GH biology from the growth component. It is not, however, a functional substitute for the hormone, and it should not be treated as acting on the GH receptor in the same manner.
For laboratories studying the broader growth-hormone axis, it may be helpful to contrast fragment-based approaches with secretagogue-based ones. Compounds that act upstream by stimulating pituitary release behave very differently from a C-terminal fragment, as discussed in the comparison of Sermorelin, Ipamorelin and CJC-1295.
Clinical Development and Its Outcome
AOD-9604 progressed into human studies, and its development history is instructive for researchers evaluating how much weight to place on early rodent data. Early human studies were reported to show that the fragment retained lipolytic properties without stimulating IGF-1 production. Metabolic Pharmaceuticals subsequently ran a larger phase IIb study in obesity, reported to include 536 participants over 24 weeks. Secondary summaries of that programme state that the trial did not produce significant weight loss relative to placebo, and development for obesity was discontinued in 2007. A 2013 review by Misra in Current Cardiology Reviews documents the programme.
This outcome is a useful reminder of the translational gap between rodent lipolysis models and human outcomes. Positive effects on body composition in obese mice did not carry through to a robust effect in a large, controlled clinical trial. The point is not to draw conclusions about any use in people, but to note that the strength of the preclinical signal should be interpreted with appropriate caution. Researchers designing experiments around AOD-9604 should treat the animal literature as hypothesis-generating rather than confirmatory.
Analytical and Anti-Doping Considerations
Because hGH and its fragments are relevant to sports anti-doping, the analytical behaviour of AOD-9604 has been studied. Orlovius and colleagues (Drug Testing and Analysis, 2013) reported that the peptide does not influence the hGH isoform immunoassay used for doping control, meaning it is not detected as hGH by that method. Cox and colleagues (Drug Testing and Analysis, 2015) subsequently characterised its detection and a urinary metabolite by mass spectrometry. These papers are not studies of efficacy, but they show how readily a 1.8 kDa peptide can be identified and distinguished from the parent hormone by mass-based methods.
Experimental Design Considerations
Several practical points follow from the literature. First, the Heffernan study used a 14-day chronic design in an obese mouse model, so findings are specific to that species, duration and route of administration, and should not be generalised to other models without direct testing. Second, because the mechanism appears to involve more than direct β3-receptor activation, investigators interested in pathway attribution may wish to include receptor-deficient or pharmacologically blocked controls, as the original authors did. Third, endpoints should be chosen with care: body weight alone is a coarse measure, and lipolysis assays, indirect calorimetry for energy expenditure and fat oxidation, and adipose tissue gene expression each answer different questions. Finally, because a large human trial did not reproduce the rodent signal, negative results and null findings are informative in this field and are worth reporting alongside positive ones.
Laboratory Handling and Storage
AOD-9604 is supplied as a lyophilised powder. As with most peptides containing cysteine and a disulfide bond, the principal stability concerns are disulfide scrambling, oxidation, and aggregation or surface adsorption in dilute solution. Lyophilised material is generally stored desiccated at −20°C and protected from light and moisture. Once reconstituted in a suitable sterile diluent, solutions are typically kept at 2–8°C, used within a limited period, and divided into aliquots to avoid repeated freeze–thaw cycles. Allowing the vial to equilibrate to room temperature before opening reduces condensation, which is a common and avoidable source of degradation.
Step-by-step technique, including diluent choice and sterile handling, is covered in the laboratory guide to reconstituting lyophilised peptides, and broader storage parameters appear in the notes on peptide storage and handling.
Verifying Identity and Purity
For a short, cyclic peptide, two analytical questions matter most. The first is purity, typically estimated by reverse-phase HPLC, where the main peak area as a proportion of total integrated area is reported. The second is identity, confirmed by mass spectrometry against the expected monoisotopic or average mass of roughly 1,815 Da. HPLC alone cannot show that the main peak is the correct molecule, and a mass spectrum can additionally reveal common impurities such as the reduced (open-chain) form, which differs by about 2 Da, oxidised variants, and truncated or deletion sequences. Researchers should confirm that any analytical documentation corresponds to the specific lot in use. Batch-level data are available on the Lab Results page.
Summary
AOD-9604 is a 16-residue, disulfide-bridged analogue of the hGH(176–191) region, modified with an N-terminal tyrosine. In mice, published work reported reductions in body weight and fat accompanied by increased β3-adrenergic receptor expression, although the mechanism is not simply direct receptor activation. Its clinical development for obesity ended after a large trial did not show significant weight loss versus placebo. For laboratory use, the most relevant considerations are careful storage that protects the disulfide bond, and mass-confirmed identity alongside HPLC purity data.
Research use only. Not a medicine, supplement or therapeutic good. Not for human or veterinary consumption.